Alamar Biosciences Inc ALMR
News
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
UPDATE — Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures

